StoneX Group
AKBA icon

StoneX Group’s Akebia Therapeutics AKBA Stock Holding History

StoneX Group’s Portfolio AKBA Stock Details AKBA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$15.9K Buy
+17,145
New +$18.4K ﹤0.01% 1783
2022
Q4 		– Sell
-10,440
Closed -$3.3K – 701
2022
Q3 		$3.3K Sell
10,440
-4,660
-31% -$1.83K ﹤0.01% 526
2022
Q2 		$5.33K Buy
+15,100
New +$6.34K ﹤0.01% 690

Other funds holding AKBA

Hennion & Walsh Asset Management
Hennion & Walsh Asset Management Parsippany, New Jersey $3.42B AUM 25.82% 1-Year Est. Return
ALPS Advisors
ALPS Advisors Denver, Colorado $21.8B AUM 17.58% 1-Year Est. Return
State of Alaska Department of Revenue
State of Alaska Department of Revenue Juneau, Alaska $9.6B AUM 34.67% 1-Year Est. Return
State of Wyoming
State of Wyoming Cheyenne, Wyoming $1.29B AUM 32.25% 1-Year Est. Return
Creative Planning
Creative Planning Overland Park, Kansas $179B AUM 16.96% 1-Year Est. Return
STRS Ohio
STRS Ohio Columbus, Ohio $27.1B AUM 34.64% 1-Year Est. Return
Choreo LLC
Choreo LLC Rockford, Illinois $9.7B AUM 18.43% 1-Year Est. Return
CWA Asset Management Group
CWA Asset Management Group Naples, Florida $3.39B AUM 25.16% 1-Year Est. Return
PFG Private Wealth Management
PFG Private Wealth Management Lutz, Florida $236M AUM 9.86% 1-Year Est. Return
ProShare Advisors
ProShare Advisors Bethesda, Maryland $69.5B AUM 31.38% 1-Year Est. Return

StoneX Group's AKBA Position: Q3 2026 in Review

StoneX Group opened a new position in Akebia Therapeutics (AKBA) in Q3 2026: 17,145 shares worth $15.9K. The stake represents ﹤0.01% of the portfolio and ranks #1783 among its holdings. This is a return to the name: StoneX Group previously reported a position in AKBA as recently as Q3 2022.

StoneX Group first reported a position in AKBA in Q2 2022 and has held it in 3 quarters since. 46 funds tracked by Wall St. Rank hold AKBA as of Q3 2026.

  • StoneX Group held 17,145 shares of Akebia Therapeutics worth $15.9K as of Q3 2026.
  • Akebia Therapeutics was a new StoneX Group position in Q3 2026.
  • Akebia Therapeutics made up ﹤0.01% of StoneX Group's portfolio in Q3 2026, its #1783 holding.
  • StoneX Group first reported a position in Akebia Therapeutics in Q2 2022 and has held it in 3 quarters since.
  • 46 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q3 2026.

Based on StoneX Group's 13F filing for Q3 2026, filed 3 Nov 2026.